STOCK TITAN

Vanguard (NASDAQ: PTCT) holds 4.87M PTC Therapeutics shares

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Vanguard Portfolio Management reports beneficial ownership of 4,871,329 shares of PTC Therapeutics common stock, representing 5.88% of the class as of 03/31/2026. The filing shows sole voting power of 66,735 shares and sole dispositive power over 4,871,329 shares. The statement clarifies holdings reflect assets managed across Vanguard affiliates and funds.

Positive

  • None.

Negative

  • None.
Beneficial ownership 4,871,329 shares Amount beneficially owned reported in Schedule 13G
Percent of class 5.88% Percent of common stock class as stated in the filing
Sole voting power 66,735 shares Shares for which Vanguard has sole power to vote
Sole dispositive power 4,871,329 shares Shares for which Vanguard has sole power to dispose
Reporting CUSIP 69366J200 CUSIP for PTC Therapeutics common stock shown on the form
Filing signature date 04/29/2026 Date the Schedule 13G was signed
beneficially owned regulatory
"this reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 4871329"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
sole voting power regulatory
"Sole power to vote or to direct the vote: 66735"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Investment Company Act of 1940 regulatory
"investment company registered under the Investment Company Act of 1940"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many PTC Therapeutics (PTCT) shares does Vanguard report owning?

Vanguard reports owning 4,871,329 shares of PTCT common stock. The filing lists this as 5.88% of the class as of 03/31/2026, with dispositive power held by Vanguard Portfolio Management and related affiliates across managed funds and accounts.

What voting and dispositive powers does Vanguard hold for PTCT?

Vanguard has sole voting power for 66,735 shares and sole dispositive power for 4,871,329 shares. The filing distinguishes voting power (ability to direct votes) from dispositive power (ability to direct sales or transfers) across Vanguard-managed accounts and affiliates.

Does Vanguard own more than 5% of PTC Therapeutics common stock?

Yes. The filing reports 5.88% ownership. The Schedule 13G lists this percentage based on 4,871,329 shares beneficially owned as of 03/31/2026, meeting the disclosure threshold for large passive investors under SEC rules.

Who filed the Schedule 13G for PTC Therapeutics on behalf of Vanguard?

The filing was made by Vanguard Portfolio Management. The signature block shows Ashley Grim, Head of Global Fund Administration, signed the form on 04/29/2026, and the filing notes holdings include shares across Vanguard funds and affiliated advisory divisions.

Does the filing indicate Vanguard controls other holders over 5% for PTCT?

No single other person is identified above 5%. The Schedule 13G states Vanguard Portfolio Management manages shares for funds and accounts; it reports that no other person known to Vanguard has the right to receive proceeds or dividends exceeding the 5% threshold.





69366J200

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Portfolio Management LLC and the following affiliates of Vanguard Portfolio Management LLC or business divisions of such affiliates: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC, or business divisions of such subsidiaries whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Portfolio Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:04/29/2026